Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Funding

Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca

Proteros biostructures GmbH ("Proteros"), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on an ongoing collaboration with AstraZeneca announced in June 2021, to include the development of small molecule inhibitors targeting a second cancer-associated epigenetic protein.

Under the terms of this new agreement, Proteros will receive research funding and will be eligible for success-based research, development, and commercial milestone payments of up to USD 75 million plus tiered royalties on annual net sales. The collaboration combines Proteros' expertise in the identification and characterization of inhibitors with novel binding mechanisms for technically challenging drug targets with AstraZeneca's leadership in the discovery and development of oncology medicines.

"The expansion of our agreement with AstraZeneca with an additional drug discovery program reflects our successful ongoing collaboration to identify selective inhibitors for notoriously challenging disease targets," said Dr. Torsten Neuefeind, CEO of Proteros. "This agreement strengthens our collaboration with a global biopharmaceutical leader and we look forward to joining forces again to discover novel inhibitors with the potential to effectively treat cancer patients in the future."

The Proteros platform will ensure high selectivity to a specific target variant within and across multiple protein families through biochemical, biophysical and cellular assays supported by rapid turnaround in the structural determination of drug-target interactions by X-ray crystallography and cryo-Electron Microscopy technologies.

About Proteros biostructures GmbH

Proteros is a privately-held company with expertise in structure-based drug discovery powered by a cutting-edge discovery engine tailored to unlock even the most technically challenging disease-relevant targets. The company's scientific rigor can accelerate overall research timelines for clients by solving challenges at the initial drug discovery and development stages. Proteros supports many of the top 20 world's largest pharmaceutical companies and more than 250 pharmaceutical and biotech partners in the U.S., Europe and Japan.

For more information please visit www.proteros.com.

These press releases may also interest you

at 08:25
151% increase in branded cannabis net revenue1 to $36.8 million in 15-month fiscal year 2022 ended March 31, 2022 (new fiscal year end) from $14.6 million in the prior 12-month year$8 million in branded cannabis net revenue for Q5, a growth of 55%...

at 08:25
Advancement in nutrition and...

at 08:17
T.D. Jakes Foundation, a 501(c)(3) nonprofit organization dedicated to building bridges to opportunity for underserved populations around the world, has named six winners of its third annual STEAM (science, technology, engineering, arts and math)...

at 08:17
Helping Hands Family (HHF) has expanded their New Jersey footprint by adding comprehensive applied behavior analysis (ABA) therapy services to both Monmouth and Middlesex County, New Jersey. This expansion reflects HHF's commitment to the autism...

at 08:15
Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, today announced the appointment of W.K. Alfred Yung, M.D., Professor, Neuro-Oncology at the MD...

at 08:15
VBI Vaccines Inc. (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3...

News published on 16 may 2022 at 05:05 and distributed by: